Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Probl Endokrinol (Mosk) ; 68(6): 89-109, 2023 Jan 24.
Article in Russian | MEDLINE | ID: covidwho-2250285

ABSTRACT

BACKGROUND: There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI). AIM: To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period. MATERIALS AND METHODS: AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected  the  data  of  hospitalized  patients  and  included  3  visits.  All  subjects  were  divided  into  3  groups:  not  overweight  (n=2139), overweight (n=2931) and obese (n=2666). RESULTS: A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (p<0.001), serum C-reactive protein over 100 mg/l (p<0.001), and the need for targeted therapy (p<0.001) in the hospitalized patients. Obesity increased the odds of myocarditis by 1,84 times (95% confidence interval [CI]: 1,13-3,00) and the need for anticytokine therapy by 1,7 times (95% CI: 1,30-2,30).The  patients  with  the  1st  and  2nd  degree  obesity,  undergoing  the  inpatient  treatment,  tended  to  have  a  higher  probability  of  a  mortality  rate.  While  in  case  of  morbid  obesity  patients  this  tendency  is  the  most  significant  (odds  ratio  -  1,78; 95% CI: 1,13-2,70). At the same time, the patients whose chronical diseases first appeared after the convalescence period, and those who had certain complaints missing before SARS-CoV-2 infection, more often had BMI of more than 30 kg/m2 (p<0,001).Additionally, the odds of death increased by 2,23 times (95% CI: 1,05-4,72) within 3 months after recovery in obese people over the age of 60 yearsCONCLUSION.  Overweight  and/or  obesity  is  a  significant  risk  factor  for severe  course  of  the  new  coronavirus  infection  and  the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.


Subject(s)
COVID-19 , Humans , Middle Aged , SARS-CoV-2 , Body Mass Index , Patient Discharge , Overweight , Hospitals , Obesity
2.
Opera Medica et Physiologica ; 9(4):25-32, 2022.
Article in English | Scopus | ID: covidwho-2205287

ABSTRACT

The paper focuses on studying the rheological properties of erythrocytes in patients with a new coronavirus infection in the acute period and during early convalescence. A significant decrease in erythrocyte membrane plasticity was found in all patients in the acute period of the disease and every second recovering patients in the early post-COVID period. An increase in the degree and rate of erythrocyte aggregation in a quarter of cases, regardless of the observation period, was accompanied by inhibition of erythrocyte disaggregation mechanisms, which can serve as a pathophysiological basis for the formation of hemorheological disorders both in the micro-and macrovasculature in the first 3 months after recovery. © 2022, Lobachevsky State University of Nizhny Novgorod. All rights reserved.

3.
Voprosy Ginekologii, Akusherstva i Perinatologii ; 21(1):85-90, 2022.
Article in Russian | EMBASE | ID: covidwho-1798615

ABSTRACT

A literature review on the effect of peri-and postmenopausal period on the course of novel coronavirus infection and post-COVID-19 syndrome was performed. The aspects of hormone replacement therapy against the background of therapy for COVID-19 and post-COVID-19 syndrome were studied. The postmenopausal period in women was found to be a risk factor for a more severe course of COVID-19. Estradiol may act as a protective factor for women with COVID-19 by regulating cellular and humoral immunity factors such as interleukin-2,-6,-8, tumor necrosis factor-α and C3. Prolonged course of COVID-19, persistence of its symptoms and development of severe post-COVID-19 syndrome are associated with female sex, with women in peri-and postmenopausal period being most vulnerable. Symptoms of estrogen deficiency and menopause may be similar to the manifestations of post-COVID-19 syndrome, and these conditions can coexist and aggravate each other. According to international experts, the use of hormone replacement therapy will help to improve the well-being of women, their quality of life, and relieve the symptoms typical of menopause and post-COVID-19 syndrome.

4.
Ter Arkh ; 94(1): 32-47, 2022 Jan 15.
Article in Russian | MEDLINE | ID: covidwho-1798590

ABSTRACT

AIM: Study the impact of various combinations of comorbid original diseases in patients infected with COVID-19 later on the disease progression and outcomes of the new coronavirus infection. MATERIALS AND METHODS: The ACTIV registry was created on the Eurasian Association of Therapists initiative. 5,808 patients have been included in the registry: men and women with COVID-19 treated at hospital or at home. CLINICALTRIALS: gov ID NCT04492384. RESULTS: Most patients with COVID-19 have original comorbid diseases (oCDs). Polymorbidity assessed by way of simple counting of oCDs is an independent factor in negative outcomes of COVID-19. Search for most frequent combinations of 2, 3 and 4 oCDs has revealed absolute domination of cardiovascular diseases (all possible variants). The most unfavorable combination of 2 oCDs includes atrial hypertension (AH) and chronic heart failure (CHF). The most unfavorable combination of 3 oCDs includes AH, coronary heart disease (CHD) and CHF; the worst combination of 4 oCDs includes AH, CHD, CHF and diabetes mellitus. Such combinations increased the risk of lethal outcomes 3.963, 4.082 and 4.215 times respectively. CONCLUSION: Polymorbidity determined by way of simple counting of diseases may be estimated as a factor in the lethal outcome risk in the acute phase of COVID-19 in real practice. Most frequent combinations of 2, 3 and 4 diseases in patients with COVID-19 primarily include cardiovascular diseases (AH, CHD and CHF), diabetes mellitus and obesity. Combinations of such diseases increase the COVID-19 lethal outcome risk.


Subject(s)
COVID-19 , Cardiovascular Diseases , Coronary Disease , Diabetes Mellitus , Heart Failure , Hypertension , Noncommunicable Diseases , Adult , Female , Humans , Male , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Chronic Disease , COVID-19/diagnosis , COVID-19/epidemiology , Hypertension/diagnosis , Hypertension/epidemiology , Prognosis , Registries , SARS-CoV-2
5.
Kardiologiia ; 61(9): 20-32, 2021 Sep 30.
Article in Russian, English | MEDLINE | ID: covidwho-1527055

ABSTRACT

Aim      To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods  The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients' privacy (data of nasal and throat smears; antibody titer; typical CT imaging features). The register territory included 7 countries: the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan. The registry design: a closed, multicenter registry with two nonoverlapping arms (outpatient arm and in-patient arm). The registry scheduled 6 visits, 3 in-person visits during the acute period and 3 virtual visits (telephone calls) at 3, 6, and 12 mos. Patient enrollment started on June 29, 2020 and was completed on October 29, 2020. The registry completion is scheduled for October 29, 2022. The registry ID: ClinicalTrials.gov: NCT04492384. In this fragment of the study of registry data, the work group analyzed the effect of therapy for comorbidities at baseline on severity and outcomes of the novel coronavirus infection. The study population included only the patients who took their medicines on a regular basis while the comparison population consisted of noncompliant patients (irregular drug intake or not taking drugs at all despite indications for the treatment).Results The analysis of the ACTIVE registry database included 5808 patients. The vast majority of patients with COVID-19 had comorbidities with prevalence of cardiovascular diseases. Medicines used for the treatment of COVID-19 comorbidities influenced the course of the infectious disease in different ways. A lower risk of fatal outcome was associated with the statin treatment in patients with ischemic heart disease (IHD); with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists and with beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation; with oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD; with oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM); and with long-acting insulins in patients with type 1 DM. A higher risk of fatal outcome was associated with the spironolactone treatment in patients with CHF and with inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD).Conclusion      In the epoch of COVID-19 pandemic, a lower risk of severe course of the coronavirus infection was observed for patients with chronic noninfectious comorbidities highly compliant with the base treatment of the comorbidity.


Subject(s)
COVID-19 , Diabetes Mellitus, Type 2 , Noncommunicable Diseases , Adult , Comorbidity , Female , Humans , Male , Pandemics , Registries , SARS-CoV-2
6.
Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Rebrov, A. P.; Tereshchenko, S. N.; Chesnikova, A. I.; Hayrapetyan, H. G.; Babin, A. P.; Bakulin, I. G.; Bakulina, N. V.; Balykova, L. A.; Blagonravova, A. S.; Boldina, M. V.; Vaisberg, A. R.; Galyavich, A. S.; Gomonova, V. V.; Grigorieva, N. U.; Gubareva, I. V.; Demko, I. V.; Evzerikhina, A. V.; Zharkov, A. V.; Kamilova, U. K.; Kim, Z. F.; Kuznetsova, T. Yu, Lareva, N. V.; Makarova, E. V.; Malchikova, S. V.; Nedogoda, S. V.; Petrova, M. M.; Pochinka, I. G.; Protasov, K. V.; Protsenko, D. N.; Ruzanov, D. Yu, Sayganov, S. A.; Sarybaev, A. Sh, Selezneva, N. M.; Sugraliev, A. B.; Fomin, I. V.; Khlynova, O. V.; Chizhova, O. Yu, Shaposhnik, I. I.; Sсhukarev, D. A.; Abdrahmanova, A. K.; Avetisian, S. A.; Avoyan, H. G.; Azarian, K. K.; Aimakhanova, G. T.; Ayipova, D. A.; Akunov, A. Ch, Alieva, M. K.; Aparkina, A. V.; Aruslanova, O. R.; Ashina, E. Yu, Badina, O. Y.; Barisheva, O. Yu, Batchayeva, A. S.; Bitieva, A. M.; Bikhteyev, I. U.; Borodulina, N. A.; Bragin, M. V.; Budu, A. M.; Burygina, L. A.; Bykova, G. A.; Varlamova, D. D.; Vezikova, N. N.; Verbitskaya, E. A.; Vilkova, O. E.; Vinnikova, E. A.; Vustina, V. V.; Gаlova, E. A.; Genkel, V. V.; Gorshenina, E. I.; Gostishev, R. V.; Grigorieva, E. V.; Gubareva, E. Yu, Dabylova, G. M.; Demchenko, A. I.; Dolgikh, O. Yu, Duvanov, I. A.; Duyshobayev, M. Y.; Evdokimov, D. S.; Egorova, K. E.; Ermilova, A. N.; Zheldybayeva, A. E.; Zarechnova, N. V.; Ivanova, S. Yu, Ivanchenko, E. Yu, Ilina, M. V.; Kazakovtseva, M. V.; Kazymova, E. V.; Kalinina, Y. S.; Kamardina, N. A.; Karachenova, A. M.; Karetnikov, I. A.; Karoli, N. A.; Karpov, O. V.; Karsiev, M. Kh, Кaskaeva, D. S.; Kasymova, K. F.; Kerimbekova, Z. B.; Kerimova, A. Sh, Kim, E. S.; Kiseleva, N. V.; Klimenko, D. A.; Klimova, A. V.; Kovalishena, O. V.; Kolmakova, E. V.; Kolchinskaya, T. P.; Kolyadich, M. I.; Kondriakova, O. V.; Konoval, M. P.; Konstantinov, D. Yu, Konstantinova, E. A.; Kordukova, V. A.; Koroleva, E. V.; Kraposhina, A. Yu, Kriukova, T. V.; Kuznetsova, A. S.; Kuzmina, T. Y.; Kuzmichev, K. V.; Kulchoroeva, C. K.; Kuprina, T. V.; Kouranova, I. M.; Kurenkova, L. V.; Kurchugina, N. Yu, Kushubakova, N. A.; Levankova, V. I.; Levin, M. E.; Lyubavina, N. A.; Magdeyeva, N. A.; Mazalov, K. V.; Majseenko, V. I.; Makarova, A. S.; Maripov, A. M.; Marusina, A. A.; Melnikov, E. S.; Moiseenko, N. B.; Muradova, F. N.; Muradyan, R. G.; Musaelian, S. N.; Nikitina, N. M.; Ogurlieva, B. B.; Odegova, A. A.; Omarova, Y. M.; Omurzakova, N. A.; Ospanova, S. O.; Pahomova, E. V.; Petrov, L. D.; Plastinina, S. S.; Pogrebetskaya, V. A.; Polyakov, D. S.; Ponomarenko, E. V.; Popova, L. L.; Prokofeva, N. A.; Pudova, I. A.; Rakov, N. A.; Rakhimov, A. N.; Rozanova, N. A.; Serikbolkyzy, S.; Simonov, A. A.; Skachkova, V. V.; Smirnova, L. A.; Soloveva, D. V.; Soloveva, I. A.; Sokhova, F. M.; Subbotin, A. K.; Sukhomlinova, I. M.; Sushilova, A. G.; Tagayeva, D. R.; Titojkina, Y. V.; Tikhonova, E. P.; Tokmin, D. S.; Torgunakova, M. S.; Trenogina, K. V.; Trostianetckaia, N. A.; Trofimov, D. A.; Tulichev, A. A.; Tupitsin, D. I.; Tursunova, A. T.; Ulanova, N. D.; Fatenkov, O. V.; Fedorishina, O. V.; Fil, T. S.; Fomina, I. Yu, Fominova, I. S.; Frolova, I. A.; Tsvinger, S. M.; Tsoma, V. V.; Cholponbaeva, M. B.; Chudinovskikh, T. I.; Shakhgildyan, L. D.; Shevchenko, O. A.; Sheshina, T. V.; Shishkina, E. A.; Shishkov, K. Yu, Sherbakov, S. Y.; Yausheva, E. A..
Russian Journal of Cardiology ; 26(4):116-131, 2021.
Article in Russian | EMBASE | ID: covidwho-1488885

ABSTRACT

The international AKTIV register presents a detailed description of out-and inpatients with COVID-19 in the Eurasian region. It was found that hospitalized patients had more comorbidities. In addition, these patients were older and there were more men than among outpatients. Among the traditional risk factors, obesity and hypertension had a significant negative effect on prognosis, which was more significant for patients 60 years of age and older. Among comorbidities, CVDs had the maximum negative effect on prognosis, and this effect was more significant for patients 60 years of age and older. Among other comorbidities, type 2 and 1 diabetes, chronic kidney disease, chronic obstructive pulmonary disease, cancer and anemia had a negative impact on the prognosis. This effect was also more significant (with the exception of type 1 diabetes) for patients 60 years and older. The death risk in patients with COVID-19 depended on the severity and type of multimorbidity. Clusters of diseases typical for deceased patients were identified and their impact on prognosis was determined. The most unfavorable was a cluster of 4 diseases, including hypertension, coronary artery disease, heart failure, and diabetes mellitus. The data obtained should be taken into account when planning measures for prevention (vaccination priority groups), treatment and rehabilitation of COVID-19 survivors.

7.
Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Rebrov, A. P.; Tereshchenko, S. N.; Che Snikova, A. I.; Hayrapetyan, H. G.; Babin, A. P.; Bakulin, I. G.; Bakulina, N. V.; Balykova, L. A.; Blagonravova, A. S.; Boldina, M. V.; Vaisberg, A. R.; Galyavich, A. S.; Gomonova, V. V.; Grigorieva, N. U.; Gubareva, I. V.; Demko, I. V.; Evzerikhina, A. V.; Zharkov, A. V.; Kamilova, U. K.; Kim, Z. F.; Kuznetsova, T. Yu, Lareva, N. V.; Makarova, E. V.; Malchikova, S. V.; Nedogoda, S. V.; Petrova, M. M.; Pochinka, I. G.; Protasov, K. V.; Protsenko, D. N.; Ruzanov, D. Yu, Sayganov, S. A.; Sarybaev, A. Sh, Selezneva, N. M.; Sugraliev, A. B.; Fomin, I. V.; Khlynova, O. V.; Chizhova, O. Yu, Shaposhnik, I. I.; Sсhukarev, D. A.; Abdrahmanova, A. K.; Avetisian, S. A.; Avoyan, H. G.; Azarian, K. K.; Aimakhanova, G. T.; Ayipova, D. A.; Akunov, A. Ch, Alieva, M. K.; Aparkina, A. V.; Aruslanova, O. R.; Ashina, E. Yu, Badina, O. Y.; Barisheva, O. Yu, Batchayeva, A. S.; Bitieva, A. M.; Bikhteyev, I. U.; Borodulina, N. A.; Bragin, M. V.; Budu, A. M.; Burygina, L. A.; Bykova, G. A.; Varlamova, D. D.; Vezikova, N. N.; Ver Bitskaya, E. A.; Vilkova, O. E.; Vinnikova, E. A.; Vustina, V. V.; Gаlova, E. A.; Genkel, V. V.; Gorshenina, E. I.; Gostishev, R. V.; Grigorieva, E. V.; Gubareva, E. Yu, Dabylova, G. M.; Demchenko, A. I.; Dolgikh, O. Yu, Duvanov, I. A.; Duyshobayev, M. Y.; Evdokimov, D. S.; Egorova, K. E.; Ermilova, A. N.; Zheldybayeva, A. E.; Zarechnova, N. V.; Ivanova, S. Yu, Ivanchenko, E. Yu, Ilina, M. V.; Kazakovtseva, M. V.; Kazymova, E. V.; Kalinina, Yu S.; Kamardina, N. A.; Karachenova, A. M.; Karetnikov, I. A.; Karoli, N. A.; Karpov, O. V.; Karsiev, M. Kh, Кaskaeva, D. S.; Kasymova, K. F.; Kerimbekova, Zh B.; Kerimova, A. Sh, Kim, E. S.; Kiseleva, N. V.; Klimenko, D. A.; Klimova, A. V.; Kovalishena, O. V.; Kolmakova, E. V.; Kolchinskaya, T. P.; Kolyadich, M. I.; Kondriakova, O. V.; Konoval, M. P.; Konstantinov, D. Yu, Konstantinova, E. A.; Kordukova, V. A.; Koroleva, E. V.; Kraposhina, A. Yu, Kriukova, T. V.; Kuznetsova, A. S.; Kuzmina, T. Y.; Kuzmichev, K. V.; Kulchoroeva, Ch K.; Kuprina, T. V.; Kouranova, I. M.; Kurenkova, L. V.; Kurchugina, N. Yu, Kushubakova, N. A.; Levankova, V. I.; Levin, M. E.; Lyubavina, N. A.; Magdeyeva, N. A.; Mazalov, K. V.; Majseenko, V. I.; Makarova, A. S.; Maripov, A. M.; Marusina, A. A.; Melnikov, E. S.; Moiseenko, N. B.; Muradova, F. N.; Muradyan, R. G.; Musaelian, Sh N.; Nikitina, N. M.; Ogurlieva, B. B.; Odegova, A. A.; Omarova, Yu M.; Omurzakova, N. A.; Ospanova, Sh O.; Pahomova, E. V.; Petrov, L. D.; Plastinina, S. S.; Pogrebetskaya, V. A.; Polyakov, D. S.; Ponomarenko, E. V.; Popova, L. L.; Prokofeva, N. A.; Pudova, I. A.; Rakov, N. A.; Rakhimov, A. N.; Rozanova, N. A.; Serikbolkyzy, S.; Simonov, A. A.; Skachkova, V. V.; Smirnova, L. A.; Soloveva, D. V.; Soloveva, I. A.; Sokhova, F. M.; Subbotin, A. K.; Sukhomlinova, I. M.; Sushilova, A. G.; Tagayeva, D. R.; Titojkina, Y. V.; Tikhonova, E. P.; Tokmin, D. S.; Torgunakova, M. S.; Trenogina, K. V.; Trostianetckaia, N. A.; Trofimov, D. A.; Tulichev, A. A.; Tupitsin, D. I.; Tursunova, A. T.; Tiurin, A. A.; Ulanova, N. D.; Fatenkov, O. V.; Fedorishina, O. V.; Fil, T. S.; Fomina, I. Yu, Fominova, I. S.; Frolova, I. A.; Tsvinger, S. M.; Tsoma, V. V.; Cholponbaeva, M. B.; Chudinovskikh, T. I.; Shakhgildyan, L. D.; Shevchenko, O. A.; Sheshina, T. V.; Shishkina, E. A.; Shishkov, K. Yu, Sherbakov, S. Y.; Yausheva, E. A..
Russian Journal of Cardiology ; 26(3):102-113, 2021.
Article in Russian | EMBASE | ID: covidwho-1488882

ABSTRACT

The organizer of the registers “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV) and “Analysis of hospitalizations of comorbid patients infected during the second wave of SARS-CoV-2 outbreak” (AKTIV 2) is the Eurasian Association of Therapists (EAT). Currently, there are no clinical registries in the Eurasian region designed to collect and analyze information on long-term outcomes of COVID-19 survivors with comorbid conditions. The aim of the register is to assess the impact of a novel coronavirus infection on long-term course of chronic non-communicable diseases 3, 6, 12 months after recovery, as well as to obtain information on the effect of comorbidity on the severity of COVID-19. Analysis of hospitalized patients of a possible second wave is planned for register “AKTIV 2”. To achieve this goal, the register will include men and women over 18 years of age diagnosed with COVID-19 who are treated in a hospital or in outpatient basis. The register includes 25 centers in 5 federal districts of the Russian Federation, centers in the Republic of Armenia, the Republic of Kazakhstan, the Republic of Kyrgyzstan, the Republic of Belarus, the Republic of Moldova, and the Republic of Uzbekistan. The estimated capacity of the register is 5400 patients.

8.
Sovrem Tekhnologii Med ; 13(4): 16-24, 2021.
Article in English | MEDLINE | ID: covidwho-1395480

ABSTRACT

The aim of the study is to assess the gender-related specifics of the COVID-19 course in patients under 55 years of age. Materials and Methods: This pilot single-center continuous retrospective non-randomized study was carried out in the repurposed infectious diseases hospital of the Privolzhsky Research Medical University (Nizhny Novgorod, Russia). The study inclusion criterion was the age of patients (up to 55 years) and confirmed coronavirus infection. In the groups based on gender differences (25 men, average age 44.0±7.8 years and 32 women, average age 41.9±9.1 years), we monitored complications of COVID-19 such as the transfer of patients to the ICU and the volume of lung damage (determined with CT scans). Results: The course of COVID-19 in male patients younger than 55 was aggravated by concomitant diseases (γ=0.36; p=0.043), among which IHD (γ=1.00; p=0.003) and liver disease (γ=0.58; p=0.007) dominated. Frequency analysis confirmed the high prevalence of coronary artery disease in men (p=0.044). Significant differences between the gender-related groups were noted in the volume of lung lesions: at admission (p=0.050), during hospital treatment (p=0.019), and at discharge (p=0.044). Using the logistic regression method, a relationship was found between the transfer of male patients to ICU and the Krebs index [y= -2.033 + 1.154 male gender + 1.539 Krebs index (χ2=5.68; p=0.059)] and comorbidity [y= -2.836 + 1.081 male gender + 2.052 comorbidity (χ2=7.03; p=0.030)]. The influence of the Krebs index and the male gender on the excess volume of lung lesions was shown [y= -1.962 + 0.575 male gender + 1.915 Krebs index (χ2=7.78; p=0.021)]. Conclusion: In individuals under the age of 55 diagnosed with COVID-19, gender is of significant importance: in men, there is a more pronounced lesion of the lung parenchyma and a more significant change in laboratory parameters. Risk factors for a severe course of COVID-19 in men are coronary artery disease and hepatobiliary disorder. Calculating the Krebs index can be used to assess the risk of disease progression.


Subject(s)
COVID-19 , SARS-CoV-2 , Sex Characteristics , Adult , COVID-19/mortality , COVID-19/therapy , Coronary Artery Disease/mortality , Coronary Artery Disease/therapy , Coronary Artery Disease/virology , Female , Humans , Male , Middle Aged , Pilot Projects , Prevalence , Retrospective Studies , Russia/epidemiology
9.
Sovrem Tekhnologii Med ; 13(3): 81-99, 2021.
Article in English | MEDLINE | ID: covidwho-1315040

ABSTRACT

The pandemic of the new coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus has spread all over the world. The large amount of information that appears every day requires comprehension and systematization. The immunological aspects of the virus-host interaction are the core issues in the effective treatment and prevention of COVID-19' development. The review analyzes the known pathways of the viral invasion and evasion, the mechanisms of the cytokine storm, endothelial damage, and hypercoagulability associated with SARS-CoV-2 infection. Clinical data from previous SARS and MERS epidemics is discussed here. We also address the therapeutic approaches based on the basic knowledge of immune response and the blood cells' immune functions, as well as the ways to reduce their hyperactivation. The use of interferon therapy, anti-inflammatory therapy, anti-cytokine therapy, neutralizing antibodies, convalescent plasma, and mesenchymal stem cells, as well as prophylactic vaccines, is discussed.


Subject(s)
COVID-19 Drug Treatment , Host-Pathogen Interactions/immunology , Pandemics , SARS-CoV-2/physiology , COVID-19/epidemiology , COVID-19/immunology , Humans
10.
Vopr Pitan ; 90(2): 40-49, 2021.
Article in Russian | MEDLINE | ID: covidwho-1239346

ABSTRACT

Post-COVID disorders syndrome (PCDS) is an umbrella term for a complex of persistent symptoms that a patient can develop after suffering from COVID-19. The aim of the research was to systematize data on the role of micronutrients in the treatment of PCDS. Material and methods. The authors carried out a systematic analysis of foreign (ncbi. nlm.nih.gov) and Russian (elibrary.ru) scientific publications. Results. The most common symptoms that can persist for a long time after a coronavirus infection can be divided into 4 groups: 1) hypoxic syndrome (respiratory and oxygen deficiency); 2) asthenic syndrome; 3) syndrome of neuropsychiatric disorders; 4) gastrointestinal symptoms. Adequate dietary intake of vitamins and mineral substances is critical for the proper functioning of the immune system and maintenance of the organism functional reserves. The optimal consumption of vitamins D, C and E, zinc and ω-3 fatty acids with ration can be useful for preventing infection, supporting immunity during COVID-19 disease and in the complex of rehabilitation of patients with PCDS. Conclusion. Intake of dietary supplements containing complex of micronutrients can be recommended as a rational adjuvant therapy during the rehabilitation period after COVID-19. However, further research is essential to determine the effective dosage of vitamins and other micronutrients to reduce the manifestations of PCDS.


Subject(s)
COVID-19/rehabilitation , Dietary Supplements , Micronutrients/therapeutic use , Nutritional Status , SARS-CoV-2 , Humans
11.
Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Tereshchenko, S. N.; Rebrov, A. P.; Chesnikova, A. I.; Fomin, I. V.; Grigorieva, N. U.; Boldina, M. V.; Vaisberg, A. R.; Blagonravova, A. S.; Makarova, E. V.; Shaposhnik, I. I.; Kuznetsova, T. Yu, Malchikova, S. V.; Protsenko, D. N.; Evzerikhina, A. V.; Petrova, M. M.; Demko, I. V.; Safonov, D. V.; Hayrapetyan, H. G.; Galyavich, A. S.; Kim, Z. F.; Sugraliev, A. B.; Nedogoda, S. V.; Tsoma, V. V.; Sayganov, S. A.; Gomonova, V. V.; Gubareva, I. V.; Sarybaev, A. Sh, Koroleva, E. V.; Vilkova, O. E.; Fomina, I. Y.; Pudova, I. A.; Soloveva, D. V.; Kiseleva, N. V.; Zelyaeva, N. V.; Kouranova, I. M.; Pogrebetskaya, V. A.; Muradova, F. N.; Badina, O. Y.; Kovalishena, O. V.; Galova, E. A.; Plastinina, S. S.; Lyubavina, N. A.; Vezikova, N. N.; Levankova, V. I.; Ivanova, S. Yu, Ermilova, A. N.; Muradyan, R. G.; Gostishev, R. V.; Tikhonova, E. P.; Kuzmina, T. Y.; Soloveva, I. A.; Kraposhina, A. Yu, Kolyadich, M. I.; Kolchinskaya, T. P.; Genkel, V. V.; Kuznetsova, A. S.; Kazakovtseva, M. V.; Odegova, A. A.; Chudinovskikh, T. I.; Baramzina, S. V.; Rozanova, N. A.; Kerimova, A. Sh, Krivosheina, N. A.; Chukhlova, S. Y.; Levchenko, A. A.; Avoyan, H. G.; Azarian, K. K.; Musaelian, Sh N.; Avetisian, S. A.; Levin, M. E.; Karpov, O. V.; Sokhova, F. M.; Burygina, L. A.; Sheshina, T. V.; Tiurin, A. A.; Dolgikh, O. Yu, Kazymova, E. V.; Konstantinov, D. Yu, Chumakova, O. A.; Kondriakova, O. V.; Shishkov, K. Yu, Fil, T. S.; Prokofeva, N. A.; Konoval, M. P.; Simonov, A. A.; Bitieva, A. M.; Trostianetckaia, N. A.; Cholponbaeva, M. B.; Kerimbekova, Zh B.; Duyshobayev, M. Y.; Akunov, A. Ch, Kushubakova, N. A.; Melnikov, E. S.; Kim, E. S.; Sherbakov, S. Y.; Trofimov, D. A.; Evdokimov, D. S.; Ayipova, D. A.; Duvanov, I. A.; Abdrakhmanova, A. K.; Aimakhanova, G. T.; Ospanova, Sh O.; Dabylova, G. M.; Tursunova, A. T.; Kaskaeva, D. S.; Tulichev, A. A.; Ashina, E. Yu, Kordukova, V. A.; Barisheva, O. Yu, Egorova, K. E.; Varlamova, D. D.; Kuprina, T. V.; Pakhomova, E. V.; Kurchugina, N. Yu, Frolova, I. A.; Mazalov, K. V.; Subbotin, A. K.; Kamardina, N. A.; Zarechnova, N. V.; Mamutova, E. M.; Smirnova, L. A.; Klimova, A. V.; Shakhgildyan, L. D.; Tokmin, D. S.; Tupitsin, D. I.; Kriukova, T. V.; Rakov, N. A.; Polyakov, D. S..
Russian Journal of Cardiology ; 25(11):98-107, 2020.
Article in Russian | Russian Science Citation Index | ID: covidwho-1094455

ABSTRACT

COVID-19 is a severe infection with high mortality. The concept of the disease has been shaped to a greater extent on the basis of large registers from the USA, Spain, Italy, and China. However, there is no information on the disease characteristics in Caucasian patients. Therefore, we created an international register with the estimated capacity of 5,000 patients - Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (AKTIV SARS-CoV-2), which brought together professionals from the Russian Federation, Republic of Armenia, Republic of Kazakhstan, and Kyrgyz Republic. The article presents the first analysis of the register involving 1,003 patients. It was shown that the most significant difference of the Caucasian population was the higher effect of multimorbidity on the mortality risk vs other registers. More pronounced effect on mortality of such diseases as diabetes, obesity, hypertension, chronic kidney disease, and age over 60 years was also revealed. COVID-19 - тяжелое инфекционное заболевание с высоким риском летального исхода. Представление о болезни во многом сформировано на основании крупных регистров, выполненных в США, Испании, Италии, КНР. Однако к настоящему времени нет данных по особенностям протекания болезни у пациентов евроазиатского региона. В связи с этим был создан международный регистр, расчетная мощность которого составляет 5000 пациентов, “Анализ динамики Коморбидных заболеваний у пациенТов, перенесшИх инфицироВание SARS-CoV-2” (AКТИВ SARS-CoV-2), работа в котором объединила специалистов Российской Федерации, Республики Армения, Республики Казахстан и Кыргызской Республики. В статье представлен первый анализ регистра, который включил данные 1003 пациентов. Показано, что самым значимым отличием евроазиатской популяции пациентов оказалось гораздо большее влияние полиморбидности на риск летального исхода в сравнении с другими регистрами, а также более выраженное влияние на риск летального исхода в евроазиатской популяции таких заболеваний, как сахарный диабет, ожирение, артериальная гипертензия, хроническая болезнь почек и возраста старше 60 лет.

12.
Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Belenkov, Y. N.; Konradi, A. O.; Lopatin, Y. M.; Tereshchenko, S. N.; Rebrov, A. P.; Chesnikova, A. I.; Fomin, I. V.; Grigorieva, N. U.; Boldina, V. M.; Vaisberg, A. R.; Blagonravova, A. S.; Makarova, E. V.; Shaposhnik, II, Kuznetsova, T. Y.; Malchikova, S. V.; Protsenko, D. N.; Evzerikhina, A. V.; Petrova, M. M.; Demko, I. V.; Saphonov, D. V.; Hayrapetyan, H. G.; Galyavich, A. S.; Kim, Z. F.; Sugraliev, A. B.; Nedogoda, S. V.; Tsoma, V. V.; Sayganov, S. A.; Gomonova, V. V.; Gubareva, I. V.; Sarybaev, A. S.; Ruzanau, D. Y.; Majseenko, V. I.; Babin, A. P.; Kamilova, U. K.; Koroleva, E. V.; Vilkova, O. E.; Fomina, I. Y.; Pudova, I. A.; Soloveva, D. V.; Doshchannikov, D. A.; Kiseleva, N. V.; Zelyaeva, N. V.; Kouranova, I. M.; Pogrebetskaya, V. A.; Muradova, F. N.; Badina, O. Y.; Kovalishena, O. V.; Gsmall a, Cyrilliclova A. E.; Plastinina, S. S.; Grigorovich, M. S.; Lyubavina, N. A.; Vezikova, N. N.; Levankova, V. I.; Ivanova, S. Y.; Ermilova, A. N.; Muradyan, R. G.; Gostishev, R. V.; Tikhonova, E. P.; Kuzmina, T. Y.; Soloveva, I. A.; Kraposhina, A. Y.; Kolyadich, M. I.; Kolchinskaya, T. P.; Genkel, V. V.; Kuznetsova, A. S.; Kazakovtseva, M. V.; Odegova, A. A.; Chudinovskikh, T. I.; Baramzina, S. V.; Rozanova, N. A.; Kerimova, A. S.; Krivosheina, N. A.; Chukhlova, S. Y.; Levchenko, A. A.; Avoyan, H. G.; Azarian, K. K.; Musaelian, S. N.; Avetisian, S. A.; Levin, M. E.; Karpov, O. V.; Sokhova, F. M.; Burygina, L. A.; Sheshina, T. V.; Tiurin, A. A.; Dolgikh, O. Y.; Kazymova, E. V.; Konstantinov, D. Y.; Chumakova, O. A.; Kondriakova, O. V.; Shishkov, K. Y.; Fil, S. T.; Prokofeva, N. A.; Konoval, M. P.; Simonov, A. A.; Bitieva, A. M.; Trostianetckaia, N. A.; Cholponbaeva, M. B.; Kerimbekova, Z. B.; Duyshobayev, M. Y.; Akunov, A. C.; Kushubakova, N. A.; Melnikov, E. S.; Kim, E. S.; Sherbakov, S. Y.; Trofimov, D. A.; Evdokimov, D. S.; Ayipova, D. A.; Duvanov, I. A.; Abdrahmanova, A. K.; Aimakhanova, G. T.; Ospanova, S. O.; Gaukhar, M. D.; Tursunova, A. T.; Kaskaeva, D. S.; Tulichev, A. A.; Ashina, E. Y.; Kordukova, V. A.; Barisheva, O. Y.; Egorova, K. E.; Varlamova, D. D.; Kuprina, T. V.; Pahomova, E. V.; Kurchugina, N. Y.; Frolova, I. A.; Mazalov, K. V.; Subbotin, A. K.; Kamardina, N. A.; Zarechnova, N. V.; Mamutova, E. M.; Smirnova, L. A.; Klimova, A. V.; Shakhgildyan, L. D.; Tokmin, D. S.; Tupitsin, D. I.; Kriukova, T. V.; Polyakov, D. S.; Karoli, N. A.; Grigorieva, E. V.; Magdeyeva, N. A.; Aparkina, A. V.; Nikitina, N. M.; Petrov, L. D.; Budu, A. M.; Rasulova, Z. D.; Tagayeva, D. R.; Fatenkov, O. V.; Gubareva, E. Y.; Demchenko, A. I.; Klimenko, D. A.; Omarova, Y. V.; Serikbolkyzy, S.; Zheldybayeva, A. E..
Kardiologiia ; 60(11):30-34, 2021.
Article in Russian | Scopus | ID: covidwho-1070011

ABSTRACT

.

13.
J. Phys. Conf. Ser. ; 1691, 2020.
Article in English | Scopus | ID: covidwho-998228

ABSTRACT

The article reveals the topic of the place and role of the Vkontakte social network in the organization of the educational process, the relevance of which was confirmed during the Covid-19 pandemic. The object of the research is digital education at Russian universities. The subject of the research is the VKontakte social network as a means of organizing the educational process. The authors share the experience of using social networks, accumulated in the process of teaching social disciplines at the Timiryazev Academy. The data proving the popularity of this network among students in Russia are presented. The main scientific result: Not only the high efficiency of using the VKontakte social network for organizing the educational process has been proven, but also a proposal is formulated to consider digital literacy and knowledge of modern digital technologies as one of the qualification requirements for higher school teachers. © Published under licence by IOP Publishing Ltd.

SELECTION OF CITATIONS
SEARCH DETAIL